APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
NCT ID: NCT02640222
Last Updated: 2022-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
321501 participants
OBSERVATIONAL
2014-01-01
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
NCT02042534
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
NCT03192215
Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention
NCT02273700
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
NCT00494871
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AC-naive treated with VKA
AC-naive treated with VKA
VKA
AC-naive treated with apixaban
AC-naive treated with apixaban
Apixaban
AC-naive treated with dabigatran
AC-naive treated with dabigatran
dabigatran
AC-naive treated with rivaroxaban
AC-naive treated with rivaroxaban
rivaroxaban
AC-experienced treated with VKA
AC-experienced treated with VKA
VKA
AC-experienced treated with apixaban
AC-experienced treated with apixaban
Apixaban
AC-experienced treated with dabigatran
AC-experienced treated with dabigatran
dabigatran
AC-experienced treated with rivaroxaban
AC-experienced treated with rivaroxaban
rivaroxaban
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VKA
Apixaban
dabigatran
rivaroxaban
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients initiated with a new AC treatment during the inclusion period, either AC naive or not
* Patients aged 18 or older at their first anticoagulant initiation during the inclusion period
* Patient diagnosed with non-valvular Atrial fibrillation (AF)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rueil-Malmaison, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CV185-285
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.